Dr Christina Yap MSci, PhD, CStat

Institute of Cancer and Genomic Sciences
Reader in Biostatistics and Clinical Trials
Principal Biostatistician

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Dr Christina Yap is a Reader in Biostatistics and Clinical Trials and the Principal Biostatistician at Cancer Research UK Clinical Trials Unit (CRCTU), within the Institute of Cancer and Genomic Sciences at the University of Birmingham. She has over 11 years of experience in statistical design and analysis of clinical trials (with 9 years of specialist experience in early phase trials). Her main expertise comprises of developing efficient trial designs and practical implementation of such designs in clinical trials. This includes adaptive designs in early phase dose-finding trials as well as multi-stage randomised Phase II/III designs; including Bayesian approaches to such settings.

She is a selected member of three National Cancer Research Institute (NCRI) Clinical Studies Group: Head and Neck Cancer Cancer, Skin Cancer and NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad). She is the statistical lead for trials in various disease areas, which include head and neck cancer, skin cancer, leukaemia and liver diseases within the trials unit in Birmingham.


  • Chartered Statistician 2010
  • PhD in Statistics, University of Glasgow, 2004
  • Associate Practitioner of the Higher Education Academy 2006
  • Master in Science (Mathematics and Statistics), University of Glasgow, 1999


  • Medicine and Surgery MBChB Year 2 Medical Statistics small group teaching
  • MSc in Clinical Oncology


  • Adaptive Trial Designs
  • Early Phase I/II trial designs, with a focus on dose-finding designs such as Continual Reassessment Method, joint evaluation of safety and activity and randomized Phase II selection designs
  • Implementation and analysis of innovative, efficient designs in clinical trials in various disease areas including leukaemia, head and neck, skin and liver
  • Bayesian designs and analysis in clinical trial
  • Flexible modelling
  • Acute and Chronic Health Effects of Air Pollution
  • Detecting discontinuity in time series and spatial data using nonparametric regression techniques

Other activities

  • Member of NCRI Non-Melanoma Skin Cancer Subgroup
  • Member of NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad)
  • Member of the MRC Hub Network Adaptive Designs Working Group
  • West Midlands Research Design Service Advisor
  • Data Monitoring Committee Member


  • Yap C., Billingham L.J., Cheung Y.K., Craddock, C. and O'Quigley, J.(2017). Dose Transition Pathways: The missing link between complex dose-finding designs and simple decision-making. Clinical Cancer Research, pp.clincanres-0582.
  • Brock K, Billingham L, Copland M, Yap C. “Implementing the EffTox Dose-Finding Design in the Matchpoint Trial”. BMC Research Methodology 2017, 17(1), 112
  • Newsome PN,Fox R,…..,Yap C  and  Forbes SJ (2017)  “REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC), a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis.”  Lancet Hep and Gastro 2017
  • Harrison C, MeadA, PanchalA, Fox S, YapC, HoultonA et al (2017) “Ruxolitinib vs Best Available Therapy in patients with ET who are intolerant or resistant to Hydroxycarbamide” Blood, 2017
  • Laing R. W., Mergental H., Yap C., Kirkham A., Whilku M., Barton D., ... & Perera M. T. P. (2017). Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. BMJ open, 7(11), e017733.
  • Pratt G., Yap C., Oldreive C., Slade D., Bishop R., Griffiths M., Dyer M. J. S., Fegan C., Oscier D., Pettitt A., Matutes E., Devereux S., Allsup D., Bloor A., Hillmen P., Follows G., Rule S., Moss P. and Stankovic T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793
  • Love, S.B., Brown, S., Weir, C.J., Harbron, C., Yap, C., Gaschler-Markefski, B., Matcham, J., Caffrey, L., McKevitt, C., Clive, S. and Craddock, C. et al (2017). Embracing model-based designs for dose-finding trials. British journal of cancer, 117(3), p.332.
  • Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P (2015). Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biology of Blood and Marrow Transplantation. 29;22(2):385-90.
  • Mussai, F. J., Yap, C., Mitchell, C., & Kearns, P. (2015): Challenges of Clinical Trial Design for Targeted Agents Against Pediatric Leukemias. Frontiers in Oncology, 4, 374
  • Yap, C., Lin, X., & Cheung, Y. K. K. (2015). Sequential Elimination in Multi-Arm Selection Trials. Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects, 81, 411-426, edited by Sverdlov, A (ed)
  • Yap C, Pettitt A and Billingham L (2013):  Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.  BMC Med Res Methodol. 2013; 13: 87.
  • Yap C, Beverland IJ, Heal MR, Cohen GR, Robertson C, Henderson DEJ, Ferguson NS, Hart CL, Morris G and Agius RM (2012): Association between long-term exposure to air pollution and specific causes of mortality in Scotland. Occupational and Environmental Medicine, 2012, 69:916-924
  • Beverland I, Robertson C, Yap C, Heal, M.R. Cohen, G.R. Henderson, D.E.J, Hart, C.L. and Agius, R.M. (2012) Comparison of models for estimation of long-term exposure to air pollution in cohort studies. Atmospheric Environment, 62. 530-539.
  • Tho LM, Glegg M, Paterson J, Yap C, MacLeod A, McCabe M, McDonald AC (2006) Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. International Journal of Radiation Oncology, Biology, Physics 66(2): 505-13
  • Beverland IJ, Cohen GR,  Heal MR, Carder M,  Yap C, Robertson C, Hart CL and Agius RM (2012): A Comparison of Short-term and Long-term Air Pollution Exposure Associations with Mortality in Two Cohorts in Scotland Environ Health Perspect. 2012; 120(9): 1280–1285.
  • Walji N, Chue A L, Yap C,  Rogers L J, El-Modir A, Chan K K, Singh K, Fernando. I N (2010): Is There a Role for Adjuvant Hysterectomy after Suboptimal Concurrent Chemoradiation in Cervical Carcinoma? Clinical Oncology 2010, 22(2), 140–146
  • King A, Barton D, Beard H, Moore J, Than N, Corbett C, Thomas J, Guo K, Guha I, Hollyman D, Stocken D, Yap C, Fox R,  Forbes SJ and Newsome PN (2015): Repeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC), a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis: study protocol for a randomised controlled trial. BMJ open 5.3 (2015): e007700.
  • Tho LM, McIntyre A, Rosst A, Gallagher C, Yap C, Ritchie DM, Canney PA (2006) Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer; An Evaluation of the “T” Grip Method of Patient Positioning. Clinical Oncology 18(2):133-8